The treatment involves receiving bevacizumab through an intravenous infusion (a drip into the vein) and taking trifluridine as oral tablets. Participants will be randomly assigned to receive either the standard treatment schedule or the new two-weekly schedule. The treatment period may last up to 24 months, during which patients will have regular check-ups to monitor their health and any side effects.

The study will track how often patients experience severe neutropenia with both treatment schedules. Other aspects being monitored include how long patients survive, whether their cancer responds to treatment, and how well patients tolerate the medications. This information will help determine if the new treatment schedule is safer and more effective than the current standard approach.

The purpose of this study is to find out whether giving chemotherapy before surgery, with or without the heated chemotherapy treatment during surgery, followed by additional chemotherapy after surgery, helps patients stay free from cancer for a longer time compared to standard treatment. The study will look at whether patients remain disease-free for 36 months after treatment. Patients will be divided into different groups by chance, similar to flipping a coin, and each group will receive a different treatment approach. Some will receive chemotherapy before surgery combined with the heated chemotherapy treatment, some will receive only chemotherapy before surgery, and others will receive standard treatment.

During the study, patients will undergo imaging tests such as CT scan or MRI to monitor their cancer, and blood samples will be collected to look for traces of cancer cells in the bloodstream. The treatment may last up to 24 weeks for some medications, and patients will be followed for several years to see how well the treatment works. The study will measure how long patients live without their cancer returning, how long they survive overall, whether the cancer comes back in the abdominal area specifically, what type of side effects occur, and how much the tumor shrinks in response to treatment before surgery.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

Participants in the study will receive the treatments over a period of up to six months. The HAIP chemotherapy involves delivering the drug directly to the liver through a special pump, while the systemic chemotherapy is given through the bloodstream. The study will monitor how well patients tolerate the treatments and whether the cancer becomes operable, meaning it can be surgically removed. The study will also track any side effects or complications that may arise from the treatments.

The trial aims to provide valuable information on the safety and effectiveness of combining HAIP chemotherapy with systemic chemotherapy for patients with colorectal cancer that has spread to the liver. By understanding how these treatments work together, the study hopes to improve outcomes for patients with this type of cancer. The study will continue until 2025, with ongoing assessments of patient responses to the treatment regimen.

Participants in the study will receive the treatment combinations, and their health will be monitored to assess how well they tolerate the medications. The study will also help determine the recommended doses of ELVN-002 when used with trastuzumab and chemotherapy. The trial is divided into two phases: Phase 1a, which focuses on safety and dose determination, and Phase 1b, which continues to evaluate safety and tolerability in a broader group of patients.

The study will involve regular check-ups and monitoring to ensure the safety of participants. This includes looking for any side effects or changes in health status. The trial aims to provide valuable information on the potential benefits and risks of using ELVN-002 in combination with other treatments for HER2-positive cancers. The estimated completion date for the study is in 2027.

The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.

The treatment being studied includes a combination of medications: FOLFOX, which is a chemotherapy regimen that includes the drugs oxaliplatin, folinic acid, and fluorouracil, and a drug called panitumumab. Panitumumab is a type of medication known as a monoclonal antibody, which is designed to target specific proteins on cancer cells. The study will use a “stop-and-go” strategy, meaning that the treatment will be paused and restarted based on the patient’s response to the therapy. If the cancer progresses while on a maintenance treatment with a drug called fluoropyrimidine, the original treatment will be reintroduced.

Participants in the study will receive the treatment over a period of time, with regular monitoring to assess how well the cancer is being controlled. The study aims to understand the duration of disease control and will also look at other outcomes such as the time until the cancer progresses, the overall survival of patients, and the quality of life during treatment. Some participants may receive a placebo as part of the study design. The trial is expected to continue until the end of 2025.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

Participants in the study will receive the treatment combination over a period of time, with INCB099280 being taken orally and Ipilimumab administered through an intravenous infusion. The study will monitor the participants for any side effects or reactions to the treatment. The goal is to find the right dose that is both safe and effective for patients. The study will also compare the effects of the treatment combination to a placebo to better understand its impact.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their treatment. These tests will help researchers understand how the treatment affects the body and whether it helps control the growth of the tumors. The study is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

The purpose of the study is to determine how effective this combination of treatments is for patients with this specific type of cancer. Patients will receive the treatments over a period of up to 24 months. The medications will be administered either through an IV infusion or taken orally, depending on the specific drug. Throughout the study, patients will have regular check-ups and scans to monitor the progress of their cancer and to see how well the treatment is working. The study aims to find out if this combination can help patients live longer without their cancer getting worse.

Participants in the study will be monitored for any side effects from the treatment, and the study will also look at how long patients live after starting the treatment. The study will help doctors understand if this combination of drugs can be a new option for treating patients with BRAF V600E mutated metastatic colorectal cancer. The results of this study could provide valuable information for future treatment strategies for this challenging type of cancer.

The purpose of the study is to evaluate how effective and safe this combination of medications is for patients with this specific type of colorectal cancer. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be closely monitored. The study will look at whether the treatment can help shrink the cancer enough to allow for surgery or other procedures that could potentially remove or destroy the cancer completely.

Throughout the study, participants will be assessed to determine if they are eligible for these additional treatments. The study will also track how well the cancer responds to the treatment, how long patients remain free of cancer progression, and overall survival rates. Additionally, any side effects or complications from the treatment will be recorded to ensure the safety of the participants. The study aims to provide valuable information on the potential benefits of this treatment combination for patients with this specific type of colorectal cancer.

The study will test romiplostim (also known as AMG 531) against a placebo. The medication will be given as an injection under the skin. Patients will receive either the study medication or placebo while undergoing their regular oxaliplatin-based chemotherapy. The treatment period will last for 21 days, and the maximum daily dose will be 10 micrograms per kilogram of body weight.

During the study, patients will continue their planned chemotherapy treatments while receiving either romiplostim or placebo. The main focus will be on whether the medication can help patients receive their full chemotherapy doses on schedule without needing to reduce or delay treatment due to low platelet counts. Doctors will monitor platelet levels and check for any side effects throughout the study period.

The trial involves several medications, each targeting specific molecular features of the cancer. These medications include Sotorasib, a selective inhibitor targeting a specific mutation in cancer cells, Durvalumab, an immune therapy given through an intravenous infusion, and DS-8201a, also known as Trastuzumab Deruxtecan, which is another type of targeted therapy. Other medications being studied are Panitumumab, Balstilimab, and Botensilimab, each administered as a solution for infusion. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

Participants in the study will receive one of these treatments for a short period before their scheduled surgery. The study will monitor how the cancer responds to the treatment by examining tissue samples from the tumor. The goal is to see if the treatment can lead to a complete or major reduction in the cancer before surgery. The study will also assess the safety and side effects of the treatments, as well as their impact on the patients’ quality of life. This research aims to improve the understanding of how these targeted treatments can benefit patients with colorectal cancer.